Conivaptan has 13 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 7 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Flibanserin, Fluticasone Propionate, Suvorexant. Patients taking Conivaptan should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 13
- Contraindicated
- 3
- Major
- 7
- Moderate
- 3
Contraindicated (3)
- Conivaptan + Flibanserin— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Conivaptan + Fluticasone Propionate— Strong CYP3A4 inhibitor may increase systemic corticosteroid effects of fluticasone propionate.
- Conivaptan + Suvorexant— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Major (7)
- Conivaptan + Erlotinib— Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration…
- Conivaptan + Erlotinib Hydrochloride— Strong CYP3A4 inhibitor that increases erlotinib exposure and risk of exposure-related toxicity. Avoid co-administration…
- Conivaptan + Mifepristone— Strong CYP3A inhibitor may increase mifepristone plasma concentrations; limit mifepristone dose to 900 mg per day when u…
- Conivaptan + Nimodipine— Strong CYP3A4 inhibitor that significantly increases nimodipine plasma concentration and blood pressure lowering effect.…
- Conivaptan + Paricalcitol— Strong CYP3A inhibitor increases paricalcitol exposure. Dose adjustment may be necessary; monitor intact PTH and serum c…
- Conivaptan + Trabectedin— Strong CYP3A inhibitor. Avoid concomitant use with trabectedin or time administration carefully if short-term use necess…
- Conivaptan + Warfarin Sodium— CYP3A4 inhibitor that increases warfarin effect and INR; requires close monitoring.
Moderate (3)
- Conivaptan + Deferasirox— Deferasirox may induce CYP3A4 resulting in decreased conivaptan concentration. Monitor for reduced effectiveness.
- Conivaptan + Digoxin— Increases digoxin serum concentration by 33% and AUC by 43%. Requires monitoring and dose adjustment.
- Conivaptan + Rydapt— Strong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse…